Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
about
RNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective.Predicting ligand-dependent tumors from multi-dimensional signaling features.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
P2860
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@ast
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@en
type
label
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@ast
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@en
prefLabel
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@ast
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@en
P2093
P2860
P356
P1476
Systems biology driving drug d ...... ntibody seribantumab (MM-121).
@en
P2093
Aaron Fulgham
Akos Czibere
Ashish Kalra
Bambang Adiwijaya
Bill Kubasek
Birgit Schoeberl
Brian Harms
Defne Yarar
Emily Pace
P2860
P2888
P356
10.1038/NPJSBA.2016.34
P577
2017-01-05T00:00:00Z
P6179
1001519990